The total return over the past 12 months is +18.84% vs. +16.94% for the S&P 500. So far it's up +17.54% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +18.84% | (53.97%) | (41.13%) | (32.00%) | N/A | N/A |
| Total Return CAGR | +18.84% | (53.97%) | (24.40%) | (22.94%) | N/A | N/A |
| Revenue CAGR | N/A | N/A | +39.89% | +78.92% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Crescent Biopharma, Inc. (CBIO)
| Year | Start price | End price | CBIO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $11.86 | $13.94 | +17.54% | +14.51% | +3.03% |
| 2025 | $24.90 | $11.86 | (52.37%) | +17.72% | (70.09%) |
| 2024 | $236.00 | $24.90 | (89.45%) | +24.89% | (114.34%) |
| 2023 | $303.00 | $236.00 | (15.92%) | +26.19% | (42.11%) |
| 2022 | $144.00 | $303.00 | +580.57% | (18.17%) | +598.74% |
| 2021 | $376.00 | $144.00 | (61.70%) | +28.74% | (90.44%) |
| 2020 | $529.00 | $376.00 | (28.92%) | +18.37% | (47.29%) |
| 2019 | $947.00 | $529.00 | (44.14%) | +31.22% | (75.36%) |
| 2018 | $1,679.00 | $947.00 | (43.60%) | (4.56%) | (39.04%) |
| 2017 | $610.00 | $1,679.00 | +175.25% | +21.70% | +153.55% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
